Skip to main content
Premium Trial:

Request an Annual Quote

Progenity Projects 2021 Revenue Growth of Up to 30 Percent

NEW YORK – Women's health diagnostic company Progenity announced on Wednesday that it expects revenue for full-year 2021 to be between $130 million and $145 million, a growth rate of up to 30 percent.

The San Diego-based firm also said it expects core molecular testing revenue to be between $115 million and $125 million and SARS-CoV-2 revenue to be between $15 million and $20 million. Core molecular testing volumes for the Innatal, Preparent, and Riscover tests are expected to be between 290,000 and 310,000 in total, and SARS-CoV-2 volumes will likely be between 275,000 and 300,000 tests.

The firm said it expects SG&A costs to be between $150 million and $160 million, with R&D costs between $50 million and $55 million.

"We expect that we will return to strong, sustained revenue and volume growth in 2021 led by expansion of our core product lines and additional testing capacity for SARS-CoV-2 test services," CEO and Cofounder Harry Stylli said in a statement. "We also remain on track to complete the clinical validation of our preeclampsia rule out test, Preecludia, by mid-year and to prepare for launch in the second half of the year."

In Thursday afternoon trading on the Nasdaq, Progenity's stock price had fallen nearly 6 percent to $5.42.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.